Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTILS.L Regulatory News (TILS)

  • There is currently no data for TILS

Director/PDMR Shareholding

12 Dec 2006 18:33

ReGen Therapeutics PLC12 December 2006 Notification of Change in Interests of Directors London: On 12 December 2006 options ("Options") were granted to directors of theCompany in respect of an aggregate of 43,200,000 ordinary shares of 0.1p each inthe Company ("Ordinary Shares"). The Options, taken with existing options andwarrants over Ordinary Shares, will, if exercised, represent 5.77 per cent ofthe then enlarged issued share capital of the Company. All Options were granted with an exercise price of 1.25p per Ordinary Share (theclosing mid-market price on 12 December 2006) and may normally be exercisedbetween 31 December 2007 and 12 December 2016. The exercise of all Options issubject to first meeting performance conditions based on product launch andachieving certain revenue and profit targets over 2007, 2008 and 2009. Prior toreceiving these grants the executive Directors cancelled all previously grantedoptions (which were not subject to performance targets). No amounts were paid for the grants themselves. Percy Lomax was granted 13,000,000 Options. Following this announcement Mr Lomaxholds a total of 2,282,069 Ordinary Shares (representing 0.33 per cent of issuedshare capital) and 13,000,000 options over Ordinary Shares in the capital of theCompany. Timothy Shilton was granted 9,000,000 Options. Following this announcement MrShilton holds a total of 500,000 Ordinary Shares (representing 0.07 per cent ofissued share capital) and 9,000,000 options over Ordinary Shares in the capitalof the Company. Norman Lott was granted 8,000,000 Options. Following this announcement Mr Lottholds a total of 182,000 Ordinary Shares (representing 0.026 per cent of issuedshare capital) and 8,000,000 options over Ordinary Shares in the capital of theCompany. Martin Small was granted 8,000,000 Options. Following this announcement Mr Smallholds a total of 2,248,736 Ordinary Shares (representing 0.32 per cent of issuedshare capital) and 8,000,000 options over Ordinary Shares in the capital of theCompany. Keith Corbin was granted 2,700,000 Options. Following this announcement MrCorbin holds a total of 1,105,000 Ordinary Shares (representing 0.16 per cent ofissued share capital) and 3,300,000 options over Ordinary Shares in the capitalof the Company. Peter Garrod was granted 2,500,000 Options. Following this announcement MrGarrod holds a total of 66,750,000 Ordinary Shares (representing 9.61 per centof issued share capital) and 2,500,000 options over Ordinary Shares in thecapital of the Company. Further Information Andrew Marshall, Greycoat Communications Tel: 020 7960 6007 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
21st Apr 20204:40 pmRNSSecond Price Monitoring Extn
21st Apr 20204:36 pmRNSPrice Monitoring Extension
21st Apr 20207:00 amRNSNotice of GM
16th Apr 20209:05 amRNSSecond Price Monitoring Extn
16th Apr 20209:00 amRNSPrice Monitoring Extension
15th Apr 20204:31 pmRNSFurther Re: Block Listing Application
15th Apr 202011:05 amRNSSecond Price Monitoring Extn
15th Apr 202011:00 amRNSPrice Monitoring Extension
15th Apr 20207:00 amRNSBlock Listing Application
15th Apr 20207:00 amRNSIssue of Equity
14th Apr 20204:41 pmRNSSecond Price Monitoring Extn
14th Apr 20204:37 pmRNSPrice Monitoring Extension
14th Apr 202011:06 amRNSSecond Price Monitoring Extn
14th Apr 202011:01 amRNSPrice Monitoring Extension
9th Apr 20207:00 amRNSTiziana Develops Treatment For COVID-19 Patients
16th Mar 20205:21 pmRNSClosing of Offer
12th Mar 20207:00 amRNSTiziana U.S. Follow-On Offering of $10 million
11th Mar 20207:00 amRNSTZLS-501 / COVID-19
20th Feb 202010:30 amRNSResult of GM
17th Feb 20207:00 amRNSProposed U.S. Public Offering of ADSs
4th Feb 202012:00 pmRNSDirector/PDMR Shareholding
3rd Feb 20207:00 amRNSNotice of GM
23rd Jan 20207:00 amRNSFiling of SEC Form F-3
21st Jan 20202:45 pmRNSDirector Appointment
14th Jan 202011:00 amRNSDirector/PDMR Shareholding
13th Jan 20207:00 amRNSProposed Cancellation from AIM
9th Jan 20207:00 amRNSFurther re: Foralumab Phase 1 Trial
2nd Jan 20203:00 pmRNSDirector/PDMR Shareholding
4th Dec 20197:00 amRNSForalumab Phase 1 Trial
20th Nov 20197:00 amRNSIssue of Equity and Directorate Change
1st Nov 20197:00 amRNSIssue of CLN
30th Oct 201910:31 amRNSChange to ADS ratio
30th Sep 20197:00 amRNSHalf-year Report
16th Sep 20197:00 amRNSFurther re: Update on IND Application
10th Sep 20197:00 amRNSPhase 1 Clinical Data
4th Sep 20197:00 amRNSPhase 2a Clinical Data
21st Aug 20194:40 pmRNSSecond Price Monitoring Extn
21st Aug 20194:35 pmRNSPrice Monitoring Extension
6th Aug 20197:00 amRNSProposed U.S. Public Offering
22nd Jul 20197:00 amRNSPhase 2a Clinical Data
1st Jul 20197:00 amRNSTeplizumab Article
28th Jun 20194:40 pmRNSSecond Price Monitoring Extn
28th Jun 20194:35 pmRNSPrice Monitoring Extension
28th Jun 201910:54 amRNSChange of Adviser
25th Jun 20197:00 amRNSDirector/PDMR Shareholding
24th Jun 20197:00 amRNSArticle on Clinical Activity of OKT3
11th Jun 20197:00 amRNSDirector/PDMR Shareholding
7th Jun 20199:44 amRNSDirector/PDMR Shareholding
3rd Jun 20197:00 amRNSPDMR Dealings
31st May 201911:05 amRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.